«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:

2022年17期

页码:

3106-3110

栏目:

论著（头颈神经肿瘤）

出版日期:

2022-07-29

文章信息/Info

Title:

The correlation between miR-1301-3p and central lymph node metastasis in papillary thyroid carcinoma

作者:

乔德辉¹; 杨 辉¹; 周 阳¹; 邓 显¹; 何雪梅²; 周翔宇¹

1.西南医科大学附属医院甲状腺外科;2.中心实验室，四川 泸州 646000

Author(s):

QIAO Dehui¹; YANG Hui¹; ZHOU Yang¹; DENG Xian¹; HE Xuemei²; ZHOU Xiangyu¹

1.Department of Thyroid Surgery;2.Central Laboratory,Affiliated Hospital of Southwest Medical University,Sichuan Luzhou 646000,China.

关键词:

甲状腺乳头状癌; miR-1301-3p; 中央区淋巴结转移; 肿瘤标志物

Keywords:

papillary thyroid carcinoma; miR-1301-3p; central lymph node metastasis; tumor marker

分类号:

R736.1

DOI:

10.3969/j.issn.1672-4992.2022.17.008

文献标识码:

A

摘要:

目的：研究miR-1301-3p在甲状腺乳头状癌（papillary thyroid carcinoma,PTC）中表达的变化，分析miR-1301-3p与PTC中央区淋巴结转移的关系。方法：选取2018年08月至2019年08月在我院诊断为“甲状腺肿瘤”的患者60例，其中PTC 30例。qRT-PCR检测miR-1301-3p在良、恶性肿瘤组织，及PTC术前、术后血清中的表达。分析miR-1301-3p与中央区淋巴结转移的关系。ROC曲线分析miR-1301-3p对甲状腺肿瘤、中央区淋巴结是否转移的诊断价值。结果：miR-1301-3p在PTC组织中表达降低（P＜0.000 1），在PTC患者术后血清中表达上升(P=0.045 5)。超声对甲状腺肿瘤的诊断效能为0.726（CI：0.627~0.810，P＜0.001）；miR-1301-3p对甲状腺肿瘤的诊断效能为0.788（CI：0.695~0.864，P＜0.001）；miR-1301-3p联合超声对甲状腺肿瘤的诊断效能为0.827（CI：0.738~0.895，P＜0.001）。miR-1301-3p在有中央区淋巴结转移的PTC中表达降低。超声对中央区淋巴结是否转移的诊断效能为0.571（CI：0.410~0.723，P=0.033 9）；miR-1301-3p对中央区淋巴结是否转移的诊断效能为0.813（CI：0.662~0.916，P＜0.001）；miR-1301-3p联合超声对中央区淋巴结是否转移的诊断效能为0.872（CI：0.733~0.955），P＜0.001）。结论：miR-1301-3p在PTC组织中表达降低，与中央区淋巴结转移相关；miR-1301-3p可提高超声对甲状腺肿瘤、中央区淋巴结是否转移的诊断效能，可能为PTC潜在的肿瘤标志物。

Abstract:

Objective:To determine the expression profile of miR-1301-3p in PTC and analyze the relationship between miR-1301-3p expression and central lymph node metastasis of PTC.Methods:60 patients diagnosed as "thyroid tumor" in our hospital from August 2018 to August 2019 were selected,including 30 cases of PTC.qRT-PCR was used to detect the expression of miR-1301-3p in benign,malignant tumor tissues,and preoperative,postoperative serum.The relationship between miR-1301-3p and central lymph node metastasis was analyzed.ROC curve was used to analyze the diagnostic value of miR-1301-3p in thyroid tumor and central lymph node.Results:The expression of miR-1301-3p decreased in PTC（P<0.000 1),and increased in the serum of postoperative（P=0.045 5).The diagnostic efficiency of ultrasound for thyroid tumor was 0.726（CI:0.627~0.810,P<0.001) and miR-1301-3p was 0.788（CI:0.695~0.864,P<0.001).miR-1301-3p combined with ultrasound was 0.827（CI:0.738~0.895,P<0.001).qRT-PCR and TCGA data analysis showed that miR-1301-3p decreased in PTC with central lymph node metastasis.The diagnostic efficiency of ultrasound for central lymph nodes was 0.571（CI:0.410~0.723,P=0.033 9) and miR-1301-3p for central lymph nodes was 0.813（CI:0.662~0.916,P＜0.001).miR-1301-3p combined with ultrasound for central lymph nodes was 0.872（CI:0.733~0.955,P<0.001).Conclusion:miR-1301-3p expression is decreased in PTC,and it is associated with central lymph node metastasis,miR-1301-3p can be used as a tumor marker for PTC diagnosis and preoperative management.

参考文献/References

［1］ FENG J,ZHOU Q,YI H,et al.A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3［J］.Cell Death Dis,2019,10(6):433.
［2］ HAUGEN BR,ALEXANDER EK,BIBLE KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2016,26(1):1-133.
［3］ HORVATH E,MAJLIS S,ROSSI R,et al.An ultransonogram reporting system for thyroid nodules stratifying cancer risk for clinical management［J］.J Clin Endocrinol Metab,2009,94(5):1748-1751.
［4］ XU SY,YAO JJ,ZHOU W,et al.Clinical characteristics and ultrasonographic features for predicting central lymph node metastasis in clinically node-negative papillary thyroid carcinoma without capsule invasion［J］.Head Neck,2019,41(11):3984-3991.
［5］ NA DK,CHOI YJ,CHOI SH,et al.Evaluation of cervical lymph node metastasis in thyroid cancer patients using real-time CT-navigated ultrasonography:preliminary study［J］.Ultrasonography,2015,34(1):39-44.
［6］ SOLORZANO CC,CARNEIRO DM,RAMIREZ M,et al.Surgeon-performed ultrasound in the management of thyroid malignancy［J］.Am Surg,2004,70(7):576-582.
［7］ DAI D,TAN Y,GUO L,et al.Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing［J］.Eur J Endocrinol,2020,182(1):111-121.
［8］ LEE RC,FEINBAUM RL,AMBROS V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14［J］.Cell,1993,75(5):843-854.
［9］ CUELLAR TL,MCMANUS MT.MicroRNAs and endocrine biology［J］.J Endocrinol,2005,187(3):327-332.
［10］ YATES LA,NORBURY CJ,GILBERT RJ.The long and short of microRNA［J］.Cell,2013,153(3):516-519.
［11］ ZHI T,JIANG K,ZHANG C,et al.MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras［J］.Am J Cancer Res,2017,7(4):982-998.
［12］ WANG L,ZHAO Y,XU M,et al.Serum miR-1301-3p,miR-335-5p,miR-28-5p,and their target B7-H3 may serve as novel biomarkers for colorectal cancer［J］.J BUON,2019,24(3):1120-1127.
［13］ PENG X,YAN B,SHEN Y.MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1［J］.Breast Cancer,2018,25(6):742-752.
［14］ YANG C,XU Y,CHENG F,et al.miR-1301 inhibits hepatocellular carcinoma cell migration,invasion,and angiogenesis by decreasing Wnt/beta-catenin signaling through targeting BCL9［J］.Cell Death Dis,2017,8(8):e2999.
［15］ ZHOU T,CAI Z,MA N,et al.A novel ten-gene signature predicting prognosis in hepatocellular carcinoma［J］.Front Cell Dev Biol,2020,8:629.
［16］ GUGNONI M,SANCISI V,GANDOLFI G,et al.Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy［J］.Oncogene,2017,36(5):667-677.
［17］ NIXON AM,PROVATOPOULOU X,KALOGERA E,et al.Circulating thyroid cancer biomarkers:Current limitations and future prospects［J］.Clinical Endocrinology,2017,87(2):117-126.
［18］ MAHMOUDIAN-SANI MR,MEHRI-GHAHFARROKHI A,ASADI-SAMANI M,et al.Serum miRNAs as biomarkers for the diagnosis and prognosis of thyroid cancer:A comprehensive review of the literature［J］.Eur Thyroid J,2017,6(4):171-177.
［19］ WEI S,YUN X,RUAN X,et al.Identification of potential pathogenic candidates or diagnostic biomarkers in papillary thyroid carcinoma using expression and methylation profiles［J］.Oncol Lett,2019,18(6):6670-6678.
［20］ PAN Q,ZHAO J,LI M,et al.Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing［J］.Carcinogenesis,2020,41(1):18-24.
［21］ 中华人民共和国国家卫生健康委员会.甲状腺癌诊疗规范(2018年版)［J］.中华普通外科学文献(电子版),2019,13(01):1-15. National Health Commission of the People's Republic of China.Standard for diagnosis and treatment of thyroid cancer（2018 Edition) ［J］.Chinese General Surgery Literature（Electronic Edition),2019,13（01):1-15.
［22］ XU F,HE H,HUANG W,et al.Decreased expression of microRNA-200 family in human breast cancer is associated with lymph node metastasis［J］.Clin Transl Oncol,2016,18(3):283-288.
［23］ LIU T,DU LT,WANG YS,et al.Development of a novel serum exosomal microRNA nomogram for the preoperative prediction of lymph node metastasis in esophageal squamous cell carcinoma［J］.Front Oncol,2020,10:573501.
［24］ QU A,YANG Y,ZHANG X,et al.Development of a preoperative prediction nomogram for lymph node metastasis in colorectal cancer based on a novel serum miRNA signature and CT scans［J］.EBioMedicine,2018,37:125-133.

备注/Memo

备注/Memo:

中国宋庆龄基金会呼吸疾病临床研究公益基金（编号：2018MZFT-176）

常用功能

更新日期/Last Update: 2022-07-29